Welcome to our dedicated page for Merus news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus stock.
Merus N.V. (MRUS) is a clinical-stage biotechnology company pioneering bispecific antibody therapeutics for cancer treatment through its Biclonics® platform. This page provides investors and researchers with centralized access to official announcements, clinical trial updates, and strategic developments shaping the company's trajectory in immuno-oncology.
Find timely updates on Merus' investigational therapies, including progress across multiple cancer indications. Track key milestones such as regulatory feedback, partnership expansions with pharmaceutical collaborators, and financial performance updates. Our aggregation ensures efficient monitoring of material events without promotional bias.
Content spans clinical data disclosures, research collaborations with industry leaders like Incyte and Lilly, intellectual property developments, and financial reporting. Each update is categorized for quick scanning while maintaining technical accuracy required for biotech analysis.
Bookmark this page for streamlined access to Merus' evolving story in multispecific antibody development. Combine our news repository with SEC filings and scientific publications for comprehensive investment research approach.
Merus N.V. (MRUS) has provided a clinical and financial update for Q3 2022. Their lead program, MCLA-129, shows clinical activity with promising early efficacy data presented at the ENA Symposium. The FDA recommends further patient enrollment in the eNRGy trial for Zenocutuzumab (Zeno) to support a Biologics License Application (BLA) for NRG1+ cancers. Collaboration revenue decreased by $7.1 million year-over-year. Operating expenses increased, leading to a greater net loss of $24.6 million. As of September 30, 2022, Merus has $372.9 million in cash, sufficient to fund operations beyond 2024.
Merus N.V. (Nasdaq: MRUS) has reported interim clinical data for MCLA-129, a bispecific antibody targeting EGFR and c-MET. The phase 1/2 trial showed a favorable safety profile with no dose-limiting toxicities. Antitumor activity was noted in heavily pretreated patients across various tumor types, including confirmed partial responses. The initial recommended dose for phase 2 is set at 1500 mg biweekly. Key details will be discussed in an investor call on October 26. These findings highlight MCLA-129's potential efficacy as a treatment for advanced solid tumors, including non-small cell lung cancer (NSCLC).
Merus N.V. (MRUS) announced promising results from the phase 1/2 trial of MCLA-129, a bispecific antibody targeting EGFR and c-MET for advanced non-small cell lung cancer (NSCLC). The drug was well-tolerated, with no dose-limiting toxicities observed. Preliminary data showed anti-tumor activity in 13 evaluable patients, with two achieving partial responses. The recommended phase 2 dose is 1500 mg. Further data will be presented at the ENA Symposium on October 28, 2022, along with an investor call detailing the program update on October 26, 2022.
Merus N.V. (Nasdaq: MRUS) announced the selection of an abstract for a poster presentation at the 34th EORTC/NCI/AACR Symposium, scheduled for October 28, 2022. The poster will focus on MCLA-129, a bispecific antibody targeting EGFR and c-MET, currently in phase 1/2 study for advanced non-small cell lung cancer (NSCLC) and other solid tumors. Preclinical studies suggest MCLA-129 may effectively treat TKI-resistant NSCLC. The abstract will be available on October 12, 2022, and the poster can be accessed during the conference and on Merus' website.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology firm, announced that CEO Bill Lundberg will participate in a panel at Citi's 17th Annual BioPharma Conference on September 8, 2022, at 2:40 p.m. ET. This event highlights the company's innovative work in developing multispecific antibodies, including Biclonics® and Triclonics®. A live webcast will be available on the company’s investor page, and an archive of the presentation will be accessible for a limited time post-event.
For more details, visit Merus’ website and social media channels.
Merus N.V. (Nasdaq: MRUS) reported a strong clinical update for its lead bispecific antibody, zenocutuzumab (Zeno), demonstrating a 34% overall response rate in NRG1+ cancer patients at the 2022 ASCO meeting. The company anticipates MCLA-129 and petosemtamab (Peto) updates in late 2022 and early 2023, respectively. Financially, Merus ended Q2 2022 with $396.8 million in cash, enough to fund operations beyond 2024, while collaboration revenue increased to $12.7 million. However, operating losses rose, totaling $31.1 million for the quarter.
Merus N.V. (MRUS) announced interim data from the phase 1/2 eNRGy trial of its bispecific antibody, Zeno, aimed at treating NRG1+ cancer. Key findings include a 34% overall response rate in 79 evaluable patients, with a median duration of response at 9.1 months. Tumor reduction was observed in 70% of patients, and Zeno was noted to be well-tolerated. These results position Zeno as a potential new standard of care. An investor call is scheduled for June 5, 2022 to discuss these findings further.
Merus N.V. (Nasdaq: MRUS) will participate in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 12:45 p.m. ET. Bill Lundberg, M.D., the President and CEO, will represent the clinical-stage oncology company known for developing innovative multispecific antibodies, including Biclonics® and Triclonics®. A webcast of the event can be accessed on the Company's Investors page, and an archived version will be available post-event.
Merus N.V. (Nasdaq: MRUS) announced positive interim results from its phase 1/2 eNRGy trial of zenocutuzumab (Zeno) for NRG1+ cancers. The data shows a robust 34% overall response rate and a median duration of response of 9.1 months. The treatment is well-tolerated, with efficacy observed across multiple NRG1+ tumor types. An oral presentation is scheduled for June 5, 2022, at ASCO, with an investor call also planned the same day to discuss these findings. The trial focuses on safety and anti-tumor activity of Zeno monotherapy in various NRG1+ cancers.
Merus N.V. (Nasdaq: MRUS) announced that its CEO, Bill Lundberg, will present at the H.C. Wainwright Global Investment Conference. This presentation will occur on May 24, 2022, with a live webcast available at 7:00 a.m. ET on the company's Investors page. An archived version will be accessible for a limited time following the event.
Merus focuses on developing innovative full-length multispecific antibodies, including its proprietary Biclonics® and Triclonics® therapies, which have demonstrated promising features in clinical studies.
FAQ
What is the current stock price of Merus (MRUS)?
What is the market cap of Merus (MRUS)?
